21:19 , Jun 13, 2019 |  BC Innovations  |  Translation in Brief

Syntrix analgesic overcomes tramadol’s dependence on CYP2D6

Bypassing the metabolic conversion required for Schedule IV opiate tramadol to achieve analgesia, Syntrix has positioned desmetramadol as a safer and more effective pain therapy. Tramadol has been positioned as less likely to cause lethal...
00:48 , May 17, 2019 |  BC Innovations  |  Tools & Techniques

Leaning on exosomes, model-informed drug development gets closer to tailoring doses to each patient

Model-informed drug development is poised to move into personalized dosing, with a little help from exosomes. An August FDA workshop aims to shed light on when and how to use these precision dosing models in...
21:05 , Mar 25, 2019 |  BC Extra  |  Clinical News

Avanir's AVP-786 meets in Phase III for Alzheimer's agitation

Avanir said one of two doses of AVP-786 met the primary endpoint of improving agitation symptoms in the Phase III 15-AVP-786-301 trial to treat agitation in patients with Alzheimer's dementia. AVP-786 comprises deuterium-modified dextromethorphan --...
23:40 , Jan 25, 2019 |  BioCentury  |  Politics, Policy & Law

101 problems with patent eligibility

The U.S. diagnostics industry is being strangled, and other life science inventions are being hobbled by, ill-conceived and contradictory patent policies. The USPTO director has signaled he wants to help, but only Congress has the...
18:46 , Jul 21, 2017 |  BC Week In Review  |  Company News

NICE final guidance recommends Sanofi's Cerdelga for Type I Gaucher's

Last month, the U.K.'s NICE issued final guidance recommending the use of Cerdelga eliglustat from the Sanofi Genzyme unit of Sanofi (Euronext:SAN; NYSE:SNY) to treat Type I Gaucher’s disease in adults who are cytochrome P450...
00:25 , Jul 21, 2017 |  BC Week In Review  |  Clinical News

Avanir begins Phase II trial of AVP-786 for neurobehavioral disinhibition from TBI

The Avanir Pharmaceuticals Inc. subsidiary of Otsuka Pharmaceutical Co. Ltd. (Tokyo, Japan) began a double-blind, placebo-controlled, U.S. Phase II trial to evaluate twice-daily oral AVP-786 (CTP-786) for up to 12 weeks in about 150 patients...
22:28 , Nov 2, 2016 |  BC Innovations  |  Distillery Techniques

Disease models

TECHNOLOGY: Transgenics and knockouts Transgenic mice expressing human PXR , NR1I3 , CYP3A4 and CYP2D6 could help predict drug-drug interactions. In mice expressing the four human genes receiving the generic estrogen receptor antagonist tamoxifen, co-treatment...
08:00 , Dec 7, 2015 |  BC Week In Review  |  Clinical News

AVP-786: Phase III started

Otsuka began the double-blind, placebo-controlled, U.S. Phase III TRIAD-1 trial to evaluate 2 doses of oral AVP-786 twice daily for 12 weeks in about 380 patients. The start of the trial triggered a $2 million...
07:00 , Aug 17, 2015 |  BC Week In Review  |  Clinical News

Nuedexta dextromethorphan/quinidine: Phase IV data

Top-line data from the open-label, U.S. Phase IV PRISM II trial in 367 patients with PBA showed that twice-daily 20/10 mg Nuedexta reduced mean CNS-LS score to 11.9 points at week 12 from 20.5 points...
08:00 , Dec 8, 2014 |  BC Week In Review  |  Company News

Avanir, Otsuka Pharmaceutical deal

Otsuka is acquiring Avanir for $17 per share in a deal valued at about $3.5 billion. The price represents a 13% premium to Avanir’s closing price of $15 on Dec. 1, before the deal was...